MA27909A1 - Derives aryles et heteroaryles trisubstitues utilises en tant que modulateurs du metabolisme et prophylaxie et traitement de troubles afferents - Google Patents

Derives aryles et heteroaryles trisubstitues utilises en tant que modulateurs du metabolisme et prophylaxie et traitement de troubles afferents

Info

Publication number
MA27909A1
MA27909A1 MA28722A MA28722A MA27909A1 MA 27909 A1 MA27909 A1 MA 27909A1 MA 28722 A MA28722 A MA 28722A MA 28722 A MA28722 A MA 28722A MA 27909 A1 MA27909 A1 MA 27909A1
Authority
MA
Morocco
Prior art keywords
prophylaxis
modulators
metabolism
treatment
related disorders
Prior art date
Application number
MA28722A
Other languages
English (en)
Inventor
Robert M Jones
Graeme Semple
Yifeng Xiong
Young-Jun Shin
Albert S Ren
Imelda Calderon
Jin Sun Karoline Choi
Beatriz Fioravanti
Juerg Lehmann
Marc A Bruce
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34083391&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27909(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MA27909A1 publication Critical patent/MA27909A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Dérivés arylés et hétéroarylés trisubstitués utilisés en tant que modulateurs du métabolisme et la prophylaxie et le traitement de troubles afférents. La présente invention se rapporte à certaines dérivés aryle et hétéroaryle trisubstitués de formule (I) qui sont des modulateurs du métabolisme. En conséquence, des composés de la présente invention sont utiles dans la prophylaxie ou le traitement de troubles du métabolisme et dans les complications de ceux-ci, tels que le diabète et l'obésité.
MA28722A 2003-07-11 2006-01-10 Derives aryles et heteroaryles trisubstitues utilises en tant que modulateurs du metabolisme et prophylaxie et traitement de troubles afferents MA27909A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48672803P 2003-07-11 2003-07-11
US48737003P 2003-07-14 2003-07-14

Publications (1)

Publication Number Publication Date
MA27909A1 true MA27909A1 (fr) 2006-05-02

Family

ID=34083391

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28722A MA27909A1 (fr) 2003-07-11 2006-01-10 Derives aryles et heteroaryles trisubstitues utilises en tant que modulateurs du metabolisme et prophylaxie et traitement de troubles afferents

Country Status (35)

Country Link
US (3) US7470699B2 (fr)
EP (2) EP1644357B9 (fr)
JP (2) JP4777244B2 (fr)
KR (1) KR20060034289A (fr)
AR (1) AR045047A1 (fr)
AT (1) ATE380809T1 (fr)
AU (2) AU2004257261C1 (fr)
BR (1) BRPI0412488A (fr)
CA (1) CA2532152C (fr)
CR (1) CR8122A (fr)
CY (1) CY1107282T1 (fr)
DE (1) DE602004010666T2 (fr)
DK (1) DK1644357T3 (fr)
EA (1) EA010690B1 (fr)
EC (1) ECSP066279A (fr)
ES (1) ES2298820T3 (fr)
HK (1) HK1083100A1 (fr)
HR (1) HRP20080087T5 (fr)
IL (1) IL172567A (fr)
IS (1) IS2572B (fr)
MA (1) MA27909A1 (fr)
ME (1) ME00572A (fr)
MX (1) MXPA06000444A (fr)
MY (1) MY141116A (fr)
NO (1) NO20060636L (fr)
NZ (2) NZ578505A (fr)
PE (1) PE20051125A1 (fr)
PL (1) PL1644357T3 (fr)
PT (1) PT1644357E (fr)
RS (1) RS20060012A (fr)
SI (1) SI1644357T1 (fr)
TN (1) TNSN06004A1 (fr)
TW (2) TW200524899A (fr)
WO (1) WO2005007647A1 (fr)
ZA (1) ZA200600009B (fr)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
BRPI0406761A (pt) 2003-01-14 2005-12-20 Arena Pharm Inc Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CN1997640A (zh) * 2004-06-04 2007-07-11 艾尼纳制药公司 作为代谢调节剂的经取代芳基和杂芳基衍生物及其相关病症的预防和治疗
DE102004042607A1 (de) 2004-09-03 2006-03-09 Bayer Healthcare Ag Substituierte Phenylaminothiazole und ihre Verwendung
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
BRPI0516407A (pt) * 2004-12-24 2008-09-02 Prosidion Ltd agonistas de receptor acoplado à proteìna g (gpr116) e uso destes para o tratamento de obesidade e diabetes
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
DOP2006000010A (es) * 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
EA200702445A1 (ru) 2005-05-09 2008-04-28 Ачиллион Фармасьютикалз, Инк. Соединения тиазола и способы их применения
US20090203676A1 (en) * 2005-06-30 2009-08-13 Oscar Barba G-protein Coupled Receptor Agonists
US20100063081A1 (en) * 2005-06-30 2010-03-11 Stuart Edward Bradly CPCR Agonists
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
NZ565898A (en) * 2005-09-16 2010-07-30 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
JP4854253B2 (ja) * 2005-09-30 2012-01-18 国立大学法人佐賀大学 脂質代謝改善用組成物
WO2007095602A2 (fr) * 2006-02-15 2007-08-23 Abbott Laboratories Nouveaux inhibiteurs d'acétyl-coa carboxylase (acc) et leur utilisation dans le traitement du diabète, de l'obésité et du syndrome métabolique
CA2641766A1 (fr) 2006-02-15 2007-08-23 Abbott Laboratories Nouveaux inhibiteurs d'acetyl-coa carboxylase (acc) et leur utilisation dans le traitement du diabete, de l'obesite et du syndrome metabolique
UA97474C2 (ru) 2006-03-31 2012-02-27 Новартис Аг Соединения для лечения нарушений, связанных с активностью dgat1
PE20071221A1 (es) * 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
ES2354390T3 (es) * 2006-04-11 2011-03-14 Arena Pharmaceuticals, Inc. Procedimientos de uso del receptor gpr119 para identificar compuestos útiles para aumentar la masa ósea en un individuo.
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
CN109503584A (zh) 2006-05-04 2019-03-22 勃林格殷格翰国际有限公司 多晶型
TW200811140A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811147A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
ES2357340T3 (es) 2006-10-18 2011-04-25 Pfizer Products Inc. Compuestos de biaril éter urea.
DE102006056740A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
DE102006056739A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
WO2008076243A2 (fr) 2006-12-14 2008-06-26 Merck & Co., Inc. Composés acyl-bipipéridinyle, compositions contenant de tels composés et procédés de traitement
MX2009011370A (es) * 2007-04-24 2009-11-05 Hoffmann La Roche Proceso para el intermediario del inhibidor proteasa de hcv.
CN101668759A (zh) 2007-05-04 2010-03-10 百时美施贵宝公司 [6,5]-双环gpr119g蛋白-偶合受体激动剂
WO2008137435A1 (fr) 2007-05-04 2008-11-13 Bristol-Myers Squibb Company Agonistes [6,6] and [6,7]-bicycliques du récepteur gpr 119 couplé à la protéine g
WO2008147557A2 (fr) 2007-05-22 2008-12-04 Achillion Pharmaceuticals, Inc. Thiazoles à substitution hétéroaryle
EA016595B1 (ru) * 2007-07-17 2012-06-29 Бристол-Маерс Сквибб Компани Способ модулирования рецептора gpr119, сопряженного с g-белком, и используемые при этом соединения
DE102007035367A1 (de) 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituierte Aryloxazole und ihre Verwendung
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
WO2009038974A1 (fr) 2007-09-20 2009-03-26 Irm Llc Composés et compositions en tant que modulateurs de l'activité de gpr119
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
US8232287B2 (en) * 2007-10-16 2012-07-31 Daiichi Sankyo Company, Limited Pyrimidyl indoline compound
JP2011500727A (ja) * 2007-10-22 2011-01-06 シェーリング コーポレイション Ｇｐｒ１１９の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用
DE102007061764A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellierte Cyanopyridine und ihre Verwendung
DE102007061763A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte azabicyclische Verbindungen und ihre Verwendung
DE102008013587A1 (de) 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2146210A1 (fr) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Procédés d'utilisation du récepteur couplé aux protéines A G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement d'états modulés par PYY
MX2010011070A (es) * 2008-04-07 2011-01-20 Irm Llc Compuestos y composiciones como moduladores de la actividad de gpr119.
WO2009129036A1 (fr) 2008-04-14 2009-10-22 Merck & Co., Inc. Composés cyclopropyliques substitués, compositions contenant de tels composés et procédés de traitement
US8791146B2 (en) 2008-05-29 2014-07-29 Bayer Intellectual Property Gmbh 2-alkoxy-substituted dicyanopyridines and their use
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
TW201006821A (en) * 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
US8536176B2 (en) 2008-08-01 2013-09-17 Nippon Chemiphar Co., Ltd. GPR119 agonist
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
WO2010048149A2 (fr) * 2008-10-20 2010-04-29 Kalypsys, Inc. Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie
US20100113480A1 (en) * 2008-10-30 2010-05-06 Michael Reuman Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists
US20100113479A1 (en) * 2008-10-30 2010-05-06 Anusuya Choudhury Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
WO2010075269A1 (fr) 2008-12-23 2010-07-01 Schering Corporation Dérivés de pyrimidine en tant que modulateurs de rcpg pour une utilisation d'un traitement de l'obésité et du diabète
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
JP2012513470A (ja) 2008-12-23 2012-06-14 シェーリング コーポレイション 二環式複素環誘導体及びその使用方法
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
DE102009006602A1 (de) 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
US8410089B2 (en) 2009-02-18 2013-04-02 Takeda Pharmaceutical Company Limited Fused heterocyclic ring compound
WO2010114957A1 (fr) 2009-04-03 2010-10-07 Schering Corporation Dérivés de pipéridine et de pipérazine bicycliques en tant que modulateurs de rcpg pour le traitement de l'obésité, du diabète et d'autres troubles métaboliques
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
TW201039827A (en) * 2009-04-15 2010-11-16 Daiichi Sankyo Co Ltd Indoline compound
SG175995A1 (en) * 2009-06-05 2011-12-29 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
WO2010146605A1 (fr) 2009-06-18 2010-12-23 Cadila Healthcare Limited Nouveaux agonistes de gpr 119
TW201111361A (en) 2009-06-24 2011-04-01 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
JP2012530758A (ja) * 2009-06-24 2012-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物、医薬組成物及びそれに関する方法
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
US8552022B2 (en) 2009-08-13 2013-10-08 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
EP2474540A4 (fr) 2009-08-31 2013-03-13 Nippon Chemiphar Co Agoniste du gpr119
MX364651B (es) 2009-11-27 2019-05-03 Boehringer Ingelheim Int Gmbh Star Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente.
EP4148045A1 (fr) 2010-01-27 2023-03-15 Arena Pharmaceuticals, Inc. Composés intermédiaires pour la préparation de l'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclopenta[b]indol-3-yl) acétique et de ses sels
US20190192510A1 (en) 2010-02-01 2019-06-27 Nippon Chemiphar Co., Ltd. Gpr119 agonist
EP2547339A1 (fr) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combinaisons d'agonistes de gpr119 et d'inhibiteurs de dpp-iv, linagliptine, pour le traitement du diabète et d'états apparentés
CN102918027A (zh) * 2010-04-06 2013-02-06 艾尼纳制药公司 Gpr119受体调节剂和对与所述受体有关的障碍的治疗
JP2013523822A (ja) 2010-04-08 2013-06-17 ブリストル−マイヤーズ スクイブ カンパニー Ｇｐｒ１１９修飾因子としてのピリミジニルピペリジニルオキシピリジノ類似体
US20130109698A1 (en) * 2010-05-03 2013-05-02 Simon Cocklin Small Molecule Inhibitors of Functions of the HIV-1 Matrix Protein
EP2566469B1 (fr) 2010-05-05 2022-12-21 Boehringer Ingelheim International GmbH Thérapie combinée
WO2011140160A1 (fr) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Composés hétéroaryles bicycliques en tant que modulateurs de gpr119
WO2011140161A1 (fr) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Analogues de benzofuranyle en tant que modulateurs de gpr119
EA201991014A1 (ru) 2010-06-24 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение диабета
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
WO2012025811A1 (fr) 2010-08-23 2012-03-01 Lupin Limited Composés indolylpyrimidines en tant que modulateurs de gpr119
US20120058983A1 (en) 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
AU2011333472A1 (en) 2010-11-26 2013-06-06 Lupin Limited Bicyclic GPR119 modulators
JP2014094886A (ja) * 2011-02-28 2014-05-22 Nippon Chemiphar Co Ltd Ｇｐｒ１１９作動薬
WO2012145361A1 (fr) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (fr) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
EP2718279B1 (fr) 2011-06-09 2016-08-10 Rhizen Pharmaceuticals SA Composés nouveaux comme modulateurs de la gpr119
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
WO2013031694A1 (fr) * 2011-08-26 2013-03-07 富山化学工業株式会社 Composé d'amine et son sel
WO2013055910A1 (fr) * 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés
KR20190007106A (ko) 2011-12-21 2019-01-21 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (fr) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
US9174965B2 (en) 2012-05-16 2015-11-03 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
KR101705390B1 (ko) * 2012-06-25 2017-02-09 강원대학교산학협력단 이중환 구조를 갖는 신규한 ｇｐｃｒ 효능제
NZ743463A (en) 2012-08-28 2019-09-27 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
WO2014074668A1 (fr) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
DK2961732T3 (en) 2013-02-28 2017-07-10 Janssen Sciences Ireland Uc SULFAMOYLARYLAMIDS AND USE THEREOF AS MEDICINES TO TREAT HEPATITIS B
WO2014161888A1 (fr) 2013-04-03 2014-10-09 Janssen R&D Ireland Dérivés de n-phénylcarboxamide et leur utilisation comme médicaments pour le traitement de l'hépatite b
LT2997019T (lt) 2013-05-17 2018-11-26 Janssen Sciences Ireland Uc Sulfamoiltiofenamido dariniai ir jų panaudojimas kaip vaistų hepatito b gydymui
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
LT3024819T (lt) 2013-07-25 2018-06-11 Janssen Sciences Ireland Uc Pirolamido dariniai, turintys glioksamido pakaitų, ir jų panaudojimas kaip vaistų hepatito b gydymui
JP6452119B2 (ja) 2013-10-23 2019-01-16 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カルボキサミド誘導体およびｂ型肝炎の処置のための医薬品としてのその使用
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
EP3102225B1 (fr) 2014-02-05 2020-03-25 Novira Therapeutics Inc. Polythérapie pour le traitement d'infections par le vhb
CN110483484A (zh) 2014-02-06 2019-11-22 爱尔兰詹森科学公司 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
WO2015128453A1 (fr) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Utilisation médicale d'un inhibiteur de dpp-4
KR101651505B1 (ko) 2014-05-02 2016-08-29 현대약품 주식회사 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
WO2016149581A1 (fr) 2015-03-19 2016-09-22 Novira Therapeutics, Inc. Dérivés d'azocane et d'azonane, et méthodes de traitement d'infections provoquées par le virus de l'hépatite b
IL285890B (en) 2015-06-22 2022-07-01 Arena Pharm Inc Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
TW201718496A (zh) 2015-09-29 2017-06-01 諾維拉治療公司 B型肝炎抗病毒劑之晶型
WO2017078352A1 (fr) 2015-11-04 2017-05-11 Hyundai Pharm Co., Ltd. Dérivé de cyclohexène, son procédé de préparation et composition pharmaceutique pour prévenir ou traiter une maladie métabolique, contenant ledit dérivé comme principe actif
AU2017248828A1 (en) 2016-04-15 2018-11-01 Janssen Sciences Ireland Uc Combinations and methods comprising a capsid assembly inhibitor
WO2017211979A1 (fr) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinaisons de linagliptine et de metformine
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CN110869362A (zh) * 2017-05-12 2020-03-06 国立研究开发法人理化学研究所 A类gpcr结合性化合物改性体
WO2018236896A1 (fr) 2017-06-19 2018-12-27 Arena Pharmaceuticals, Inc. Composés et procédés pour le traitement de nafld et de nash
CN111867582A (zh) 2018-03-14 2020-10-30 爱尔兰詹森科学公司 衣壳组装调节剂给药方案
MA55020A (fr) 2019-02-22 2021-12-29 Janssen Sciences Ireland Unlimited Co Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
JP2022532526A (ja) 2019-05-06 2022-07-15 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｈｂｖ感染又はｈｂｖ誘導性疾患の処置において有用なアミド誘導体

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH389134A (de) 1960-03-15 1965-03-15 Ciba Geigy Verfahren zur Herstellung neuer Anthrachinonküpenfarbstoffe
CH499528A (de) 1965-10-22 1970-11-30 Ciba Geigy Ag Verfahren zur Herstellung neuer Pyrimidine
CH480410A (de) 1967-01-09 1969-10-31 Geigy Ag J R Verfahren zur Herstellung von wasserlöslichen Azopyrimidinfarbstoffen
CA961052A (en) 1967-01-12 1975-01-14 Max Schellenbaum N-2-ethylhexyl-n'-aryl ureas and preparation containing them
FR1593586A (fr) 1967-10-17 1970-06-01
US3608087A (en) 1968-06-21 1971-09-21 Merck & Co Inc Feed compositions
US3887329A (en) 1969-05-05 1975-06-03 Ciba Geigy Ag Hexamethyl phosphotriamide-dye compositions
BE756953A (fr) 1969-10-02 1971-04-01 Merck & Co Inc Potentialisation d'antibiotiques
US3686238A (en) 1970-01-19 1972-08-22 Syntex Corp Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US3852434A (en) 1970-09-11 1974-12-03 Merck & Co Inc Potentiation of ({31 ) cis-1,2-epoxypropyl)phosphonic acid and analogues thereof
US3690834A (en) 1971-01-11 1972-09-12 Syva Co Ligand determination with spin labeled compounds by receptor displacement
US3966744A (en) 1971-01-11 1976-06-29 Syva Company Spin labeled compounds
DE2106585A1 (de) 1971-02-11 1972-08-24 Farbenfabriken Bayer Ag, 5090 Leverkusen Aminothiodiazole und Thiodiazol-Azofarbstoffe
CH560197A5 (en) 1971-05-17 1975-03-27 Ciba Geigy Ag 2-alkylthio-4,6-bis (subst amino)-5-nitropyrimidines - - herbicides
CH558137A (de) 1971-05-17 1975-01-31 Ciba Geigy Ag Mittel zur beeinflussung des pflanzenwachstums.
US3966764A (en) 1972-07-10 1976-06-29 Syva Company Ligand determination of spin labeled compounds by receptor displacement-amphetamine analogs
US3849420A (en) 1972-10-20 1974-11-19 Dow Chemical Co Bis-(alkylthio-and alkylsulfonyl)-pentachloroquinolines
CH574206A5 (fr) * 1972-11-16 1976-04-15 Ciba Geigy Ag
DE2340569C2 (de) 1973-08-10 1982-12-02 Bayer Ag, 5090 Leverkusen Azofarbstoffe
AT340933B (de) 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
CH584739A5 (fr) 1973-12-21 1977-02-15 Ciba Geigy Ag
US4101541A (en) 1973-12-21 1978-07-18 Ciba-Geigy Corporation 3-Cyano-1,2,4-thiadiazolyl-5-czo dyestuffs
FR2258841B1 (fr) 1974-01-29 1977-11-04 Ugine Kuhlmann
AT327605B (de) 1974-05-06 1976-02-10 Ciba Geigy Ag Mittel zur hemmung des pflanzenwachstums
AU492126B2 (en) 1974-05-14 1975-11-20 Ciba-Geigy Ag Nitropyrimidine derivatives
FR2306697A1 (fr) 1975-04-10 1976-11-05 Sogeras Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants
DE2731264A1 (de) 1977-07-11 1979-02-01 Boehringer Mannheim Gmbh Neue 1-acyl-2-cyanaziridine, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zubereitungen
JPS6038696B2 (ja) 1977-12-09 1985-09-02 コニカ株式会社 ハロゲン化銀カラ−写真感光材料
US4242507A (en) 1978-02-23 1980-12-30 Fujisawa Pharmaceutical Co., Ltd. Sulfonic acid esters
DE2831580C2 (de) * 1978-07-18 1980-09-18 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und Reagens zur Bestimmung von Glycerin
DE2831850A1 (de) 1978-07-20 1980-02-07 Basf Ag N-arylsulfonylpyrrole, ihre herstellung und diese enthaltende therapeutische mittel
DE2906603A1 (de) 1979-02-21 1980-09-04 Boehringer Mannheim Gmbh N-substituierte aziridin-2-carbonsaeurederivate, verfahren zu deren herstellung sowie diese substanzen enthaltende arzneimittel
DOP1981004033A (es) 1980-12-23 1990-12-29 Ciba Geigy Ag Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
DE3334455A1 (de) * 1983-03-04 1984-09-06 Bayer Ag, 5090 Leverkusen Guanidin - derivate
ZA848275B (en) 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
DE3406329A1 (de) 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
JPS6157587A (ja) 1984-08-29 1986-03-24 Shionogi & Co Ltd 縮合複素環誘導体および抗潰瘍剤
PH22302A (en) 1985-02-11 1988-07-22 Fujisawa Pharmaceutical Co Piperidine compounds
IE860511L (en) 1985-03-01 1986-09-01 Alfa Farmaceutici Spa "Benzoyl urea derivatives having anti-tumor activity"
DE3601196A1 (de) 1986-01-17 1987-07-23 Merck Patent Gmbh 1,4-dihydropyridine
CA1340284C (fr) 1987-03-19 1998-12-22 Zeneca Inc. Diones cycliques avec substitution, herbicides
DE68926687T2 (de) 1988-01-11 1997-03-06 Fuji Photo Film Co Ltd Verfahren zur Erzeugung von extrem hochkontrastreichen negativen Bildern
NZ238863A (en) 1990-07-19 1993-03-26 Janssen Pharmaceutica Nv Substituted thiazolyl and pyridinyl derivatives
WO1992012976A1 (fr) * 1991-01-16 1992-08-06 Yoshitomi Pharmaceutical Industries, Ltd. Compose de pyridine utilise comme medicament selectif et nouveau compose de pyridine
CA2070978A1 (fr) 1991-06-11 1992-12-12 William J. Greenlee Inhibiteurs cycliques de la renine
JPH0533359A (ja) 1991-08-02 1993-02-09 Kubota Corp 全旋回型の小型バツクホウ
EP0556889A1 (fr) 1992-02-18 1993-08-25 Duphar International Research B.V Méthode pour la préparation de aryl(homo)préparation
TW237456B (fr) 1992-04-09 1995-01-01 Ciba Geigy
JPH05333599A (ja) 1992-05-29 1993-12-17 Mitsui Toatsu Chem Inc イエロー色系カラートナー用色素及び組成物
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
NZ314207A (en) 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
DE4241632A1 (de) 1992-12-10 1994-06-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
JPH0753546A (ja) 1993-08-09 1995-02-28 Kuraray Co Ltd ジアリール置換複素環化合物およびその医薬用途
GB9400889D0 (en) 1994-01-18 1994-03-16 Sandoz Ltd Novel compounds
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
CN1118454C (zh) * 1994-09-09 2003-08-20 日本新药株式会社 杂环衍生物和医药
DK0801059T3 (da) 1994-11-29 2001-09-24 Dainippon Pharmaceutical Co Indolderivat
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
AU707323B2 (en) 1995-03-10 1999-07-08 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1996033994A1 (fr) 1995-04-28 1996-10-31 Nippon Soda Co., Ltd. Derives amino-substitues, leur procede de preparation et herbicide
WO1996036613A1 (fr) 1995-05-19 1996-11-21 Nippon Soda Co., Ltd. Derives d'acides benzoiques substitues, procede de production desdits derives et herbicides
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US6956047B1 (en) 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
DK0852580T3 (da) 1995-08-31 2000-11-20 Lonza Ag Fremgangsmåde til fremstilling af dihydroxypyrimidin-derivater
ES2193266T3 (es) 1995-10-26 2003-11-01 Mitsubishi Pharma Corp Compuestos de feniletanolamina, utiles como agonistas de beta3, procedimiento para su produccion e intermedios de su produccion.
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
USH2007H1 (en) 1996-01-19 2001-12-04 Fmc Corporation Insecticidal N-heterocyclylalkyl-or N-[(polycyclyl)alkyl]-N′substituted piperazines
DE19602095A1 (de) 1996-01-22 1997-07-24 Bayer Ag Halogenpyrimidine
PL191271B1 (pl) 1996-02-07 2006-04-28 Neurocrine Biosciences Inc Pochodna pirazolopirymidyny i jej zastosowanie oraz kompozycja farmaceutyczna
US5948786A (en) * 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US6008234A (en) 1996-09-12 1999-12-28 Berlex Laboratories, Inc. Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
IL123232A0 (en) 1997-02-11 1999-11-30 Lilly Co Eli Medicament for inhibiting glucose metabolism deterioration
JPH11193277A (ja) 1997-05-14 1999-07-21 Nippon Soda Co Ltd ピリミジン誘導体、その製法および有害生物防除剤
DE19737723A1 (de) 1997-08-14 1999-02-18 Bayer Ag Methoximinomethyloxadiazine
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
US6239126B1 (en) 1998-12-17 2001-05-29 American Home Products Corporation Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives
EP1040831A3 (fr) 1999-04-02 2003-05-02 Pfizer Products Inc. Utilisation d'antagonistes du facteur de libération de la corticotropine pour la prévention de la mort subite
EP1074549B1 (fr) 1999-08-06 2003-11-19 F. Hoffmann-La Roche Ag Tétrahydro-benzo(d)azépines et leurs utilisations en tant qu'antagonistes du récepteur de glutamate métabotropique
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
JP2001089452A (ja) 1999-09-22 2001-04-03 Sankyo Co Ltd ピリミジン誘導体
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
DE19962936A1 (de) 1999-12-24 2001-06-28 Bayer Ag Neue beta-Aminosäureverbindungen als Integrinantagonisten
EA200300834A1 (ru) * 2000-01-18 2004-02-26 Пфайзер Продактс Инк. Антагонисты фактора, высвобождающего кортикотропин
ES2278755T3 (es) 2000-05-18 2007-08-16 Bayer Healthcare Ag Regulacion del receptor acoplado a proteinas g de tipo dopamina humano.
EP1294704A1 (fr) 2000-06-29 2003-03-26 Abbott Laboratories Derives d'aryle phenylheterocyclyle sulfures et leur utilisation en tant qu'agents immunosuppresseurs anti-inflammatoires inhibant l'adherence cellulaire
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
EP1340749A4 (fr) 2000-11-17 2007-09-05 Takeda Pharmaceutical Derives d'isoxazole
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
AU3113902A (en) 2000-12-21 2002-07-01 Bristol Myers Squibb Co Thiazolyl inhibitors of tec family tyrosine kinases
CN1245391C (zh) 2001-06-01 2006-03-15 弗·哈夫曼-拉罗切有限公司 用作谷氨酸受体的嘧啶、三嗪和吡嗪衍生物
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
JP4510442B2 (ja) * 2001-06-26 2010-07-21 ブリストル−マイヤーズ スクイブ カンパニー ＴＮＦ−α発現のＮ−ヘテロ環インヒビター
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
EP1499598A1 (fr) 2002-04-18 2005-01-26 Ucb, S.A. Composes chimiques a double activite, procedes de leur preparation et compositions pharmaceutiques
GB0214254D0 (en) 2002-06-20 2002-07-31 Glaxo Group Ltd Chemical compounds
SE0201976D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
US7144888B2 (en) 2002-08-08 2006-12-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
JP2006507302A (ja) * 2002-10-30 2006-03-02 メルク　エンド　カムパニー　インコーポレーテッド キナーゼ阻害剤
BRPI0406761A (pt) 2003-01-14 2005-12-20 Arena Pharm Inc Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia
PL378295A1 (pl) * 2003-02-24 2006-03-20 Arena Pharmaceuticals, Inc. Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu glukozy oraz profilaktyka i leczenie zaburzeń tego metabolizmu
JP2004269468A (ja) 2003-03-12 2004-09-30 Yamanouchi Pharmaceut Co Ltd ピリミジン誘導体又はその塩
JP2004269469A (ja) 2003-03-12 2004-09-30 Yamanouchi Pharmaceut Co Ltd ピリミジン誘導体又はその塩
DK1475094T3 (da) 2003-05-06 2010-11-22 Univ Palackeho Pyrazolo[4,3-d]pyrimidiner, fremgangsmåde til deres fremstilling samt deres anvendelse
US7083933B1 (en) 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
SE0301368D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
RS20060018A (en) * 2003-07-14 2007-12-31 Arena Pharmaceuticals Inc., Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005023762A1 (fr) 2003-09-04 2005-03-17 Abbott Laboratories Derives de pyrrolidine-2-carbonitrile et leur utilisation comme inhibiteurs de la dipeptidyle peptidase-iv (dpp-iv)
EP1699777B1 (fr) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidylpeptidase
GB0324236D0 (en) 2003-10-16 2003-11-19 Astrazeneca Ab Chemical compounds
PE20050444A1 (es) 2003-10-31 2005-08-09 Takeda Pharmaceutical Compuestos de piridina como inhibidores de la peptidasa
BRPI0416444B8 (pt) 2003-11-12 2021-05-25 Chiesi Farm Spa composto de ácido borônico heterocíclico, composição farmacêutica, e, combinação farmacêutica compreendendo o mesmo
WO2005058849A1 (fr) 2003-12-15 2005-06-30 Glenmark Pharmaceuticals Ltd. Nouveaux inhibiteurs de dipeptidyle peptidase iv, leur procede de preparation et compositions les contenant
DE10360835A1 (de) 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
US20080227786A1 (en) 2004-01-16 2008-09-18 Ferlita Russell R Novel Crystalline Salts of a Dipeptidyl Peptidase-IV Inhibitor
WO2005075426A1 (fr) 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Nouveaux inhibiteurs de dipeptidyle peptidase iv, leur procedes de preparation et compositions en comportant
MY144044A (en) 2004-06-10 2011-07-29 Irm Llc Compounds and compositions as protein kinase inhibitors
MX2007003330A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
CA2582447C (fr) 2004-10-01 2012-04-17 Merck & Co., Inc. Aminopiperidines utilisees comme inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete
CN101084018B (zh) 2004-11-03 2013-12-18 艾尼纳制药公司 用于治疗胰岛素相关病症的gpr41和其调节剂
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
EP1838703A2 (fr) 2005-01-19 2007-10-03 Neurogen Corporation Analogues de piperazinyl-pyridine à substitution hétéroaryle
ATE527253T1 (de) 2005-07-01 2011-10-15 Irm Llc Pyrimidin-substituierte benzimidazolderivate als proteinkinasehemmer
US7326715B2 (en) 2005-09-23 2008-02-05 N.V. Organon 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
TW200745055A (en) 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
JPWO2007063868A1 (ja) 2005-11-29 2009-05-07 東レ株式会社 アリールメチレンウレア誘導体及びその用途
UA96936C2 (uk) 2005-12-29 2011-12-26 Лексикон Фармасьютикалз, Инк. Поліциклічні похідні амінокислот і їх застосування
BRPI0621226A2 (pt) 2006-01-19 2012-07-10 Orchid Reseach Lab Ltd compostos heterociclos
US7863446B2 (en) 2006-01-19 2011-01-04 Orchid Research Laboratories Limited Heterocycles
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
TW200811140A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
US20100035863A1 (en) 2006-09-12 2010-02-11 Ucb Pharma, S.A. 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
WO2008076243A2 (fr) 2006-12-14 2008-06-26 Merck & Co., Inc. Composés acyl-bipipéridinyle, compositions contenant de tels composés et procédés de traitement
US8093246B2 (en) 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US20080194545A1 (en) 2007-02-08 2008-08-14 Trius Therapeutics Antimicrobial compositions and methods of use
WO2008115973A2 (fr) 2007-03-20 2008-09-25 Vertex Pharmaceuticals Incorporated Aminopyrimidines utiles en tant qu'inhibiteurs de kinase
JP2010524962A (ja) 2007-04-17 2010-07-22 バーテックス ファーマシューティカルズ インコーポレイテッド オーロラキナーゼ阻害剤のための創薬法
MX2009013982A (es) 2007-06-26 2010-04-09 Lexicon Pharmaceuticals Inc Composiciones que comprenden inhibidores de triptofano hidroxilasa.
MX2009013990A (es) 2007-06-26 2010-03-30 Lexicon Pharmaceuticals Inc Metodos para tratar enfermedades y trastornos mediados por serotonina.

Also Published As

Publication number Publication date
JP2007528856A (ja) 2007-10-18
IS8290A (is) 2006-02-09
SI1644357T1 (sl) 2008-06-30
ECSP066279A (es) 2006-07-28
IL172567A0 (en) 2006-04-10
IS2572B (is) 2010-01-15
WO2005007647A1 (fr) 2005-01-27
DK1644357T3 (da) 2008-04-21
JP2011148836A (ja) 2011-08-04
KR20060034289A (ko) 2006-04-21
AU2010200364A1 (en) 2010-02-18
TW200838861A (en) 2008-10-01
TW200524899A (en) 2005-08-01
AU2004257261A1 (en) 2005-01-27
US7838525B2 (en) 2010-11-23
RS20060012A (en) 2007-12-31
CR8122A (es) 2006-05-29
WO2005007647A9 (fr) 2005-04-07
HRP20080087T3 (en) 2008-03-31
MXPA06000444A (es) 2006-08-23
DE602004010666T2 (de) 2009-01-22
EP1923390A1 (fr) 2008-05-21
NO20060636L (no) 2006-03-31
US7470699B2 (en) 2008-12-30
US20070155763A1 (en) 2007-07-05
PE20051125A1 (es) 2006-01-28
EA200600235A1 (ru) 2006-08-25
CA2532152A1 (fr) 2005-01-27
HRP20080087T5 (hr) 2010-05-31
AU2004257261B2 (en) 2009-11-05
EP1644357A1 (fr) 2006-04-12
ES2298820T3 (es) 2008-05-16
NZ544140A (en) 2009-10-30
CY1107282T1 (el) 2012-11-21
CA2532152C (fr) 2013-10-01
ME00572A (en) 2011-12-20
ZA200600009B (en) 2007-03-23
US20050070562A1 (en) 2005-03-31
AR045047A1 (es) 2005-10-12
DE602004010666D1 (de) 2008-01-24
US20110112060A1 (en) 2011-05-12
AU2004257261C1 (en) 2010-07-22
TNSN06004A1 (en) 2007-10-03
AU2004257261B8 (en) 2010-05-13
PT1644357E (pt) 2008-03-19
EP1644357B9 (fr) 2010-03-24
IL172567A (en) 2011-01-31
HK1083100A1 (en) 2006-06-23
EA010690B1 (ru) 2008-10-30
JP4777244B2 (ja) 2011-09-21
PL1644357T3 (pl) 2008-05-30
NZ578505A (en) 2011-03-31
ATE380809T1 (de) 2007-12-15
EP1644357B1 (fr) 2007-12-12
MY141116A (en) 2010-03-15
BRPI0412488A (pt) 2006-09-19
US8546429B2 (en) 2013-10-01

Similar Documents

Publication Publication Date Title
MA27909A1 (fr) Derives aryles et heteroaryles trisubstitues utilises en tant que modulateurs du metabolisme et prophylaxie et traitement de troubles afferents
MA28130A1 (fr) Derives aryle et heteroaryle condenses utilises comme modulateurs du metabolisme et prophylaxie et traitement des troubles metaboliques.
MA27707A1 (fr) Derives aryles et heteroaryles tri-substitues en position 1,2,3 en tant que modulateurs de metabolisme et prophylaxie et traitement de troubles lies au metabolisme
MA30289B1 (fr) Dérivés d'amines
TNSN04211A1 (fr) Phenylacetamides substitues et leurs utilisation en tant qu'activateurs de la glucokinase
EA200501348A1 (ru) Замещенные арильные и гетероарильные производные, используемые в качестве модуляторов метаболизма глюкозы и для профилактики и лечения связанных с ним расстройств
MA31683B1 (fr) Composes et procedes pour moduler fxr
TNSN04164A1 (fr) Inhibiteurs de acc.
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA27736A1 (fr) Dérivés de l'acide 3-méthyl-2-(3-(2-phényloxazol-4-ylméthoxy)cyclohexanecarbonylaminobutyrique et composés apparentés utilisés comme modulateurs de PPAR destinés au traitement du diabète de type 2 et de l'artériosclérose
BR0214023A (pt) Derivados de 1,2,4-tiadiazólio como moduladores de receptor de melanocortina
TNSN02014A1 (fr) Composes nouveaux agonistes de ppar et compositions les contenant
TNSN02032A1 (fr) Derives de glutaramide a substituant n-phenpropylcyclopentyle nouveaux, et compositions les contenant.
MA27448A1 (fr) Derives de pyridine modulateurs du recepteur cb2
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
TNSN98082A1 (fr) DERIVES SUBSTITUES EN C - 4 DE 9 - DESOXO - 9a - aza - 9a HOMOERYTHROMYCINE A.
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA28747B1 (fr) Dérivés de pyridine
TNSN07070A1 (fr) Composes aminoheteroaryliques enantiomeriquement purs servant d'inhibiteurs de proteine-kinases
MA51669B1 (fr) Modulateurs de tmem16a
MA30782B1 (fr) Amides substitues, procede de production et d'utilisation desdits amides
TNSN05249A1 (fr) Benzopyrannes utiles pour le traitement d'etats inflammatoires
BR0112093A (pt) Derivados de sulfonil-pirrolidina úteis no tratamento de distúrbios neurológicos
ATE332887T1 (de) Naturstoffe und deren derivate zur prävention und behandlung von herzkreislauf-, leber- und nierenerkrankungen und für kosmetische anwendungen
TN2009000112A1 (fr) Derives de sulfonamides servant d'agonistes adrenergiques et d'antagonistes muscariniques